6 news items
MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance
MIRA
22 Jul 24
at: www.mirapharmaceuticals.comKetamir-2 and MIRA-55 are in early-stage preclinical development. There is no assurance that the products will proceed through
Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC
MIRA
15 Jul 24
-55 are in early-stage preclinical development. There is no assurance that the products will proceed through development or will receive FDA approval
Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year
MIRA
10 Jun 24
-2 and MIRA-55 are in early-stage preclinical development. There is no assurance that the products will proceed through
Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance
MIRA
29 May 24
are in early-stage preclinical development. There is no assurance that the products will proceed through development or will receive FDA approval
MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog
MIRA
21 May 24
.
Ketamir-2 and MIRA-55 are in early-stage preclinical development. There is no assurance that the products
o02db
MIRA
20 May 24
-clinical development. There is no assurance that the products will proceed through development or will receive FDA approval for marketing
- Prev
- 1
- Next